IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

July 2019

IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer.

Read the press release here (in swedish)

Business Development Manager Asia

IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF.

Two new publications on UBC Rapid

A publication presented in Entropy shows the value of UBC® Rapid

IDL Biotech

Skip this intro